Altimmune (ALT) Cash & Equivalents (2010 - 2026)

Altimmune (ALT) has 17 years of Cash & Equivalents data on file, last reported at $97.6 million in Q1 2026.

• Quarterly Cash & Equivalents rose 98.59% year-over-year to $97.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.6 million (up 98.59% YoY) and the FY2025 annual result came in at $43.8 million, up 18.37% from the prior year.
• Cash & Equivalents advanced to $97.6 million in Q1 2026 per ALT's latest filing, from $43.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $183.1 million in Q2 2025 and bottomed at $31.5 million in Q3 2024.
• The 5-year median for Cash & Equivalents is $97.6 million (2026), against an average of $95.5 million.
• The widest annual swing landed in 2024, when Cash & Equivalents slumped 72.65%; it then jumped 220.29% in 2025.
• Tracing ALT's Cash & Equivalents over 5 years: stood at $111.1 million in 2022, then increased by 21.62% to $135.2 million in 2023, then tumbled by 72.65% to $37.0 million in 2024, then advanced by 18.37% to $43.8 million in 2025, then jumped by 123.04% to $97.6 million in 2026.
• Per Business Quant, the three latest ALT Cash & Equivalents figures stand at $97.6 million (Q1 2026), $43.8 million (Q4 2025), and $61.3 million (Q3 2025).

Peer Comparison